The University of Saskatchewan needed a compelling proposal to secure investment from the Canada First Research Excellence Fund (CFREF) for a water security research program.
The Saskatchewan Centre for Patient-Oriented Research (SCPOR) needed a third-party evaluation to understand its impact to date and optimize its strategy.
Facing the need to de-risk the development of new vaccines, a top-10 biopharma company required help articulating the strategic vision and business case for a translational research public-private partnership.
The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact.
A large biotech firm needed support in developing an evidence-based policy narrative in preparation for the launch of a CAR T-cell therapy for a rare form of cancer.
Creating a Global Policy Strategy to Support the Launch of an Innovative Influenza Antiviral for a Top-5 Pharma Company
The global headquarters of a top-5 pharmaceutical company needed to develop a global policy strategy to support the launch of a new treatment for influenza.
A US-based biotech company required support to identify, evaluate and prioritize novel immunotherapies and targeted oncology drug candidates to supplement its clinical pipeline.
The International AIDS Society (IAS) required support to develop a 5-year strategy for the Global HIV Vaccine Enterprise (the Enterprise)—a long-time convenor and facilitator for the HIV vaccine R&D field.
To support a mid-stage clinical development program, a top-5 pharmaceutical company engaged Shift Health to obtain an understanding of physicians’ decision-making process with alternative therapies.